The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrestAlexandre Pichard, Jean‐Pierre Pouget, Manuel Bardiès et al.|Leukemia|2019Cited by 25
Realistic multi-cellular dosimetry for<sup>177</sup>Lu-labelled antibodies: model and applicationS Marcatili, Manuel Bardiès, Alexandre Pichard et al.|Physics in Medicine and Biology|2016Cited by 21
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitroMarion Masitsa Malenge, Jostein Dahle, Astri Fjelde Maaland et al.|PLoS ONE|2022Cited by 3
Abstract 5432: Targeted alpha therapy with 212Pb-NNV003 in treatment of NHLJostein Dahle, Julien Torgue, Amal Saidi et al.|Cancer Research|2022Cited by 1
Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma XenograftsHelèn Heyerdahl, Jostein Dahle, Ada H. V. Repetto‐Llamazares|Journal of Cancer Biology and Therapeutics|2018Cited by 1